CovarsaDx to Exhibit at ADLM 2026 Conference

Anaheim, CA – CovarsaDx, a contract research organization focused exclusively on in vitro diagnostics (IVD) and diagnostic medical devices, announced its participation in the Association for Diagnostics & Laboratory Medicine (ADLM) Annual Scientific Meeting & Clinical Lab Expo. The event is scheduled to take place at the Anaheim Convention Center from July 26–30, 2026.

At Booth #1477, the CovarsaDx team will showcase the company's end-to-end approach to IVD and diagnostic clinical research. Discussions will cover regulatory strategy, study design, site management, enrollment, data management, and submission-ready reporting. The company also plans to address regulatory pathway planning, protocol development, and evidence strategies for 510(k), De Novo, and PMA programs.

CovarsaDx will also feature SitePath™, its dedicated site operations function, and TrialPathDx™, its proprietary Clinical Trial Management System. These capabilities are designed to support proactive study and site management.

Further bolstering its expertise, CovarsaDx recently welcomed Lisa Baumhardt as Senior Director, Regulatory Affairs. Baumhardt, who brings over 30 years of experience in medical devices, IVDs, and digital health, will be present at the ADLM event. "Lisa's background is exactly what our sponsors need in a regulatory partner," said Chermaen Lindberg, President and CEO of CovarsaDx. Mark Boyle, Chief Operations Officer, added, "Successful regulatory submissions require more than just good study execution. Clinical, regulatory, and quality strategies must work together from the beginning."

CovarsaDx encourages attendees to schedule dedicated meeting times in advance by contacting studies@covarsadx.com. Walk-ins are also welcome at Booth #1477.